Strumento inattivo

Altre lingue Profound Medical Corp Toronto S.E.

Azioni

PRN

CA74319B1067

Prezzo di chiusura Toronto S.E. Altri mercati azionari
- ^CAD	-

15/05	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
14/05	Aggiornamento settoriale: i titoli del settore sanitario sono rimasti fermi martedì prima del mercato	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS	15/05
Sector Update: Health Care Stocks Steady Premarket Tuesday	14/05
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell	14/05
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	14/05
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	14/05
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan	14/05
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	14/05
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	09/05
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	09/05
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	09/05
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance	09/05
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	09/05
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	06/05
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	06/05
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	06/05
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum	06/05
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow	22/04
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	07/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Profound Medical Corp Toronto S.E.

Azioni

PRN

CA74319B1067

Altre lingue

Filtri